Management of intrahepatic cholangiocarcinoma: a review for clinicians

Gastroenterology report, Journal Year: 2025, Volume and Issue: 13

Published: Jan. 1, 2025

Abstract Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy that arises from second-order biliary epithelial cells. Its incidence gradually increasing worldwide. Well-known risk factors have been described, although in many cases, they are not identifiable. Treatment options continuously expanding, but the prognosis of iCCA remains dismal. R0 resection only curative treatment, a limited number patients can benefit it. Frequently, major hepatectomies needed to completely remove tumour. This could contraindicate surgery or increase postoperative morbidity with chronic disease and small remnant volume. In cases anticipated inadequate future remnant, regenerative techniques may be used expand resectability. The role extent lymphadenectomy still matters debate. Improvements diagnosis better understanding genetic profiles might lead optimized surgical approaches drug therapies. neoadjuvant adjuvant therapies broadening, gaining more acceptance clinical practice. Combining locoregional novel drugs, such as checkpoint-inhibitors molecular-targeted molecules, improve treatment survival rates. Liver transplantation, after very poor initial results, now receiving attention for unresectable early (i.e. <2 cm) cirrhotic livers, showing outcomes comparable those hepatocellular carcinoma. Ongoing prospective protocols testing efficacy transplantation unresectable, advanced tumours confined liver, sustained response treatment. changing landscape, aim our work review state-of-the-art medical iCCA.

Language: Английский

Significance of anatomical resection and wide surgical margin for HCC patients with MVI undergoing laparoscopic hepatectomy: a multicenter study

European Journal of Surgical Oncology, Journal Year: 2024, Volume and Issue: 51(1), P. 109353 - 109353

Published: Nov. 1, 2024

Language: Английский